Ascendia Pharmaceutical Solutions discloses $4.1m equity financing
The drug formulation and manufacturing company reported $4,084,536 in equity sales to three investors.
Ascendia Pharmaceutical Solutions disclosed $4,084,536 in equity financing in a Form D filed on July 24, 2026. The filing, submitted under its legal name Ascendia Pharmaceuticals, reports three investors and a first sale on June 26.
The New Jersey company develops drug formulations and manufactures clinical materials for pharmaceutical and biotechnology customers. Its technologies include lipid nanoparticles and nanosized drug particles, used to address delivery and dissolution challenges.